Australia's most trusted
source of pharma news
Tuesday, 17 September 2024
Posted 18 June 2024 AM
Telix Pharmaceuticals has made a last-minute decision to pull its own Nasdaq listing after being forced to offer discounts to find buyers among US investors.
The diagnostic and therapeutic radiopharmaceuticals developer is currently Australia's second largest ASX listed biotech and was hoping to raise US$200 million through the Initial Public Offering (IPO).
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.